Clinical trial
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
NCT07391774
Study timeline
Study start (actual)2026-08-10Date precision: day
Registry last updated2026-10-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Anatomic Stage II Breast Cancer AJCC v8unresolved
HER2-Negative Breast Carcinomaunresolved
Interventions
AnastrozoleDRUG · verified · RxNorm: anastrozole
Biospecimen CollectionPROCEDURE
Bone ScanPROCEDURE
ChemotherapyDRUG
Computed TomographyPROCEDURE
ExemestaneDRUG · verified · RxNorm: exemestane
LetrozoleDRUG · verified · RxNorm: letrozole
Oncotype DX Breast Cancer AssayPROCEDURE
Positron Emission TomographyPROCEDURE
Ribociclib SuccinateDRUG · verified · RxNorm: ribociclib succinate
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Mapped research locations
Des MoinesIowa, United States5New YorkNew York, United States4RichmondVirginia, United States3DaytonOhio, United States3San JuanPuerto Rico3SpringfieldIllinois, United States3ChicagoIllinois, United States2PhiladelphiaPennsylvania, United States2BaltimoreMaryland, United States2SacramentoCalifornia, United States2Kansas CityMissouri, United States2Saint PaulMinnesota, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07391774 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.